Soluble guanylyl cyclase, a heterodimeric enzyme, is the most important intracellular target for the signalling molecule nitric oxide (NO). NO stimulates the enzyme by binding to a prosthetic heme group. The identity of the axial heme ligand, however, is still unknown. Here we show that guanylyl cyclase mutated at the residue His 105 on the beta 1 subunit, a mutant that we have shown before to contain no heme after purification [Wedel, B., Humbert, P., Harteneck, C., Foerster, J., Malkewitz, J., Böhme, E., Schultz, G. & Koesling, D. (1994) Proc. Natl Acad. Sci. USA 91, 2592-2596] can be reconstituted with heme. The reconstituted mutant remains NO-insensitive and displays an ultraviolet absorption spectrum consistent with an altered axial coordination. Thus, this residue is a strong candidate for the axial heme-ligating residue and appears to be necessary for NO stimulation. Apart from the axial heme ligand, the role of the enzyme's two subunits, alpha 1 and beta 1, in heme binding has not been clarified to date. To address this question, we purified mutant heterodimers in which the non-conserved amino termini of either alpha 1 (131 residues deleted), or beta 1 (64 residues) have been deleted. These deletion mutants had previously been found to be marginally (alpha 1 truncated) or not at all NO sensitive (beta 1 truncated) in cytosolic fractions [Wedel, B., Harteneck, C., Foerster, J., Friebe, A., Schultz, G. & Koesling, D. (1995) J. Biol. Chem. 270, 24871-24875]. Here, we show that the purified enzyme truncated on alpha 1 has a significantly reduced capacity to bind heme which explains the reduced NO sensitivity. By contrast, the beta 1-truncated enzyme binds an amount of heme comparable to the wild type but is only marginally NO-responsive and displays a shift in the heme ultraviolet absorption maximum indicative of altered heme coordination. In conclusion, the heme binding site of soluble guanylyl cyclase requires the presence of both subunits in full length to be able to bind wild-type quantities of heme and to be capable of mediating the NO-heme-induced stimulation. Despite some structural similarity, both subunits appear to participate differently in NO-heme-mediated enzyme regulation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1432-1033.1996.0380h.x | DOI Listing |
G3 (Bethesda)
January 2025
Department of Neurobiology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093.
The conserved MAP3K DLKs are widely known for their functions in synapse formation, axonal regeneration and degeneration, and neuronal survival, notably under traumatic injury and chronic disease conditions. In contrast, their roles in other neuronal compartments are much less explored. Through an unbiased forward genetic screening in C.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Cardiology Service, Hospital Universitario de La Princesa, Madrid, Spain.
Introduction: Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.
Material And Methods: This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023.
Purpose: To investigate the effects of C-type natriuretic peptide (CNP) on human granulosa cell growth and elucidate its regulatory mechanisms.
Methods: A human non-luteinizing granulosa cell line (HGrC) developed from small antral follicles was used to assess the impact of CNP on cell proliferation and estrogen synthesis. cGMP production via the guanylate cyclase domain of the CNP receptor, natriuretic peptide receptor 2 (NPR2), was confirmed.
Hypertens Res
January 2025
Department of Pathological and Molecular Pharmacology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Poor blood pressure control in treated patients with hypertension is an important topic in the field of hypertension, and an unmet need for new therapeutic drugs remains. Soluble guanylate cyclase (sGC), a key signal transduction enzyme responsible for vasodilation, has attracted increasing interest as a therapeutic target in various cardiovascular diseases. Two different sGC agonists, sGC stimulators and activators, can increase its enzymatic activity in reduced and oxidized/apo forms, respectively.
View Article and Find Full Text PDFiScience
January 2025
Physiologisches Institut, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
NO-sensitive guanylyl cyclase (NO-GC) is involved in the (patho)physiology of the mammalian heart. However, little is known about the individual cardiac cell types that express NO-GC and the role of the enzyme in cardiac fibrosis. Here, we describe the cellular expression of NO-GC in healthy and fibrotic murine myocardium; these data were compared with scRNA-seq data.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!